Form 4: Apellis Pharmaceuticals Acquired by Biogen

Director A. Sinclair Dunlop reports the disposal of all equity holdings in Apellis Pharmaceuticals following its acquisition by Biogen.

Summary

• Apellis Pharmaceuticals, Inc. has been acquired by Biogen Inc. via a merger agreement dated March 31, 2026.
• The transaction was finalized on May 14, 2026, with Apellis becoming a wholly-owned subsidiary of Biogen.
• Shareholders received $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• Reporting person A. Sinclair Dunlop disposed of 161,567 shares of common stock and various stock options as part of the merger.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a definitive cash exit and potential upside through CVRs.

Positives

• Shareholders received a definitive cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share if specific milestones are met.
• The acquisition provides a clear exit strategy for investors at a set valuation.

Negatives

• Stock options with an exercise price equal to or greater than $45.00 were cancelled without consideration.
• The company is no longer a publicly traded entity, removing future growth potential for current shareholders.

Risks

• The $4.00 per share CVR is contingent upon specific milestones, which may not be achieved.
• The CVR is non-transferable, limiting liquidity for the additional potential payout.

Future Outlook

Apellis Pharmaceuticals is now a wholly-owned subsidiary of Biogen, and its future performance will be integrated into Biogen's operations.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large-cap biopharmaceutical companies (Biogen) consolidating mid-cap innovators (Apellis) to bolster their pipelines, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• The use of CVRs in this deal is consistent with recent biopharma M&A trends where valuation gaps exist regarding future clinical or regulatory milestones.
• The $41.00 cash offer represents a standard premium-based exit for shareholders in the biotech sector.

Stakeholder Impact

• Shareholders have been cashed out of their positions.
• Employees and management are now part of the Biogen organization.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, CVR, Tender Offer